1. Home
  2. RNR vs NBIX Comparison

RNR vs NBIX Comparison

Compare RNR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenaissanceRe Holdings Ltd.

RNR

RenaissanceRe Holdings Ltd.

N/A

Current Price

$323.44

Market Cap

13.6B

Sector

Finance

ML Signal

N/A

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

N/A

Current Price

$141.13

Market Cap

15.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RNR
NBIX
Founded
1993
1992
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6B
15.5B
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
RNR
NBIX
Price
$323.44
$141.13
Analyst Decision
Hold
Strong Buy
Analyst Count
18
28
Target Price
★ $347.56
$208.40
AVG Volume (30 Days)
242.8K
★ 978.0K
Earning Date
10-27-2026
10-27-2026
Dividend Yield
★ 0.52%
N/A
EPS Growth
★ 59.13
41.95
EPS
★ 6.57
3.30
Revenue
★ $12,848,074,000.00
$161,626,000.00
Revenue This Year
N/A
$36.49
Revenue Next Year
N/A
$16.51
P/E Ratio
$49.62
★ $41.88
Revenue Growth
9.86
★ 977.51
52 Week Low
$231.17
$122.14
52 Week High
$340.24
$186.12

Technical Indicators

Market Signals
Indicator
RNR
NBIX
Relative Strength Index (RSI) 41.04 38.83
Support Level $316.11 $125.18
Resistance Level $333.73 $142.82
Average True Range (ATR) 5.86 3.63
MACD -1.24 -0.24
Stochastic Oscillator 15.65 27.51

Price Performance

Historical Comparison
RNR
NBIX

About RNR RenaissanceRe Holdings Ltd.

RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: